The increase in the thromboxane (TX) A 2 metabolite, TXB 2 , observed in the placebo-group at the end of the treatment was not observed in the n-3 PUFA treated group, but failed to reach significance ( Fig. 1 , middle panel).
← all excerpts
Decreased oxidative stress and altered urinary oxylipidome by intravenous omega-3 fatty acid emulsion in a randomized controlled trial of older subjects hospitalized for COVID-19.
1
—
—